I bet if you looked at the RAP prospectus prior to relisting you would find the same scenario. No revenue, most of the trials were done since relist, etc.
just saying you can't use RAP in its current status to compare to ePat pre listing.
MNQ Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held